Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
[This corrects the article DOI: 10.1371/journal.pone.0183023.].
Main Authors: | Marius Ilie, Shirin Khambata-Ford, Christiane Copie-Bergman, Lingkang Huang, Jonathan Juco, Veronique Hofman, Paul Hofman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5640228?pdf=render |
Similar Items
-
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01) -
Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD‐L1 immunohistochemistry for predicting response to anti‐PD‐1/PD‐L1 immunotherapy
by: Weixian Hu
Published: (2020-01-01) -
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
by: Naoya Maekawa, et al.
Published: (2021-02-01) -
PD-L1 Immunohistochemistry Comparability and Their Correlation with Clinical Characteristics in NSCLC
by: Chiao-En Wu, et al.
Published: (2020-01-01) -
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)